Leadership Overview
PCI Pharma Services has 8 executives leading key functions including information technology, operations, finance, clinical quality, clinical trials, commercial packaging, and general leadership.
Driven by a commitment to advancing healthcare, PCI Pharma Services provides integrated services from formulation development to commercial manufacturing and distribution, impacting global patient access to critical medicines.
Driven by a commitment to advancing healthcare, PCI Pharma Services provides integrated services from formulation development to commercial manufacturing and distribution, impacting global patient access to critical medicines.
Leadership Roles at PCI Pharma Services
Tom De Weerdt - Chief Financial Officer
Tom De Weerdt, the Chief Financial Officer at PCI Pharma Services, directs all financial operations and strategic fiscal planning for the organization. De Weerdt manages budgeting, forecasting, financial reporting, and capital allocation, ensuring the company's financial health and sustainable growth. This critical role supports the company's expansive service offerings, from formulation development to commercial manufacturing and distribution, by providing the financial framework for operational investments and expansion. By guiding financial strategy, Tom De Weerdt enables PCI Pharma Services to invest in advanced technologies and infrastructure across its United States and European locations. The Chief Financial Officer's expertise is fundamental to maintaining investor confidence and driving profitability within the competitive global healthcare industry.
Gil Valadez - Chief Operating Officer
Gil Valadez, the Chief Operating Officer at PCI Pharma Services, orchestrates the company's extensive operational activities across its global network. Valadez manages the day-to-day execution of services including commercial manufacturing, packaging, and supply chain management, ensuring adherence to the highest industry standards. This executive leadership drives efficiency and scalability in production and distribution, directly supporting the company's mission to provide integrated solutions to the healthcare industry. By overseeing complex logistical operations and manufacturing processes, Gil Valadez ensures timely delivery of critical pharmaceutical products to clients worldwide. The Chief Operating Officer's strategic oversight is vital for maintaining operational excellence and expanding PCI Pharma Services' market reach throughout the United States and Europe.
Laila Rubi - Chief Operating Officer, Clinical Quality Documents
Laila Rubi, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, spearheads the operational management of clinical quality documentation. Rubi ensures that all documentation related to clinical trial supply and pharmaceutical services meets stringent regulatory requirements and internal quality standards. This leadership position is crucial for maintaining compliance and operational integrity within the clinical trial services division, supporting clients in navigating complex regulatory landscapes. By overseeing the meticulous management of quality documents, Laila Rubi safeguards the integrity of clinical trial data and ensures the smooth progression of research and development projects. The Chief Operating Officer's dedication to quality underpins PCI Pharma Services' commitment to providing reliable and compliant solutions to the global healthcare sector.
Brian Keesee - President, Clinical Trial Services
Brian Keesee, the President, Clinical Trial Services at PCI Pharma Services, leads the strategic direction and operational execution of the company's clinical trial supply services. Keesee oversees the end-to-end management of clinical trial logistics, including packaging, labeling, storage, and distribution of investigational medicinal products. This executive leadership ensures that clients receive comprehensive support throughout their clinical development programs, facilitating the timely and secure delivery of materials to trial sites across the globe. By focusing on innovation and efficiency within clinical trial supply, Brian Keesee enhances the company's ability to support complex global studies. The President's commitment to operational excellence drives client success and reinforces PCI Pharma Services' position as a key partner in pharmaceutical research.
Alice Farley - President
Alice Farley, the President at PCI Pharma Services, provides overarching leadership and strategic guidance for key business segments. Farley directs initiatives aimed at enhancing service integration and expanding market presence across the United States and Europe. This executive role involves fostering strong client relationships and ensuring the company's operational capabilities align with evolving industry demands for pharmaceutical services. By championing strategic growth and operational excellence, Alice Farley contributes significantly to PCI Pharma Services' mission of supporting global healthcare companies. The President's focus on driving value and innovation solidifies the company's reputation as a premier provider of integrated pharmaceutical solutions.
Yann Ghafourzadeh - President, Commercial Packaging Technology
Yann Ghafourzadeh, the President, Commercial Packaging Technology at PCI Pharma Services, drives innovation and operational excellence in the company's commercial packaging solutions. Ghafourzadeh oversees the development and implementation of advanced packaging technologies designed to ensure product integrity, patient safety, and market appeal for pharmaceutical clients. This leadership role is critical in optimizing packaging processes for commercial manufacturing, supporting the efficient and compliant distribution of finished drug products. By focusing on cutting-edge packaging solutions, Yann Ghafourzadeh enhances PCI Pharma Services' ability to meet diverse client needs and regulatory requirements across global markets. The President's strategic vision strengthens the company's comprehensive offering in pharmaceutical manufacturing and supply chain management.
Halley Liu - President
Halley Liu, the President at PCI Pharma Services, provides executive leadership and strategic direction for critical operational areas. Liu focuses on enhancing the company's integrated service model, ensuring seamless delivery of solutions from formulation development through commercial manufacturing and distribution. This role is pivotal in driving operational efficiency and fostering strategic partnerships within the global healthcare industry. By guiding key business initiatives, Halley Liu supports PCI Pharma Services' commitment to quality, reliability, and innovation. The President's leadership contributes to the company's sustained growth and its ability to meet the complex demands of pharmaceutical clients worldwide.
Edward DePrimo - Chief Information Officer
Edward DePrimo, the Chief Information Officer at PCI Pharma Services, directs the company's global information technology strategy and infrastructure. DePrimo oversees the implementation and maintenance of all digital systems, ensuring robust cybersecurity measures and data integrity across all operational sites in the United States and Europe. This leadership role supports the company's integrated service model by enabling seamless data flow for analytical services, formulation development, and clinical trial supply chain management. By optimizing technology solutions, Edward DePrimo enhances operational efficiency and supports the secure handling of sensitive client information, directly contributing to PCI Pharma Services' reputation for reliability and innovation in the pharmaceutical services sector. The Chief Information Officer's focus remains on leveraging technology to drive business growth and improve client experiences.
Explore Leadership Teams in Manufacturing
Kyowa Kirin is a global specialty pharmaceutical company focused on antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. They are headquartered in Tokyo, Japan.
Company Leadership SS
SK
TS
KS
Merz North America Inc is a company that operates in the Pharmaceuticals industry. It employs 1000to4999 people and has 500Mto1G of revenue. The company is headquartered in Raleigh, North Carolina.
Company Leadership
PU
Parabolic Drugs Limited is a vertically integrated, research-based pharmaceutical manufacturer and exporter, specializing in the production of over 50 active pharmaceutical ingredients (APIs) and intermediates across various therapeutic segments. The company operates four large-scale facilities, including three state-of-the-art manufacturing plants and a custom synthesis and R&D center. With a focus on backward and forward integration, world-class infrastructure, and strong R&D capabilities, Parabolic Drugs is committed to delivering high-quality products. Their diverse product portfolio is supported by intellectual property rights, including Drug Master Files (DMFs) and patents for novel processes.
Company Leadership AN
AJ
RG
YB
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding PCI Pharma Services Top Executives and Leadership Team
Unlock more people and company data
